Physician profile
Eric Chang
NPI 1962856674
$8,163.72
in general payments reported to CMS, 2019-2025
18 companies · $54.17 in 2025
The $54.17 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $131 · 2021: $575 · 2022: $5,671 · 2023: $586 · 2024: $1,147 · 2025: $54.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $1,063 · Food and Beverage: $723.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $1,063.30 |
| Food and Beverage | $723.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $5,862.07 | 2021-2022 | |
| Boston Scientific Corporation | $1,063.30 | 2024 | |
| Janssen Pharmaceuticals, INC | $291.95 | 2020-2023 | Xarelto |
| Merz North America, INC. | $190.70 | 2021 | |
| Penumbra, INC. | $111.06 | 2023 | Indigo System |
| Cordis US Corp. | $102.06 | 2023 | Mynx Control |
| Merck Sharp & Dohme LLC | $97.33 | 2023 | Verquvo |
| Cathworks, INC. | $84.12 | 2023 | Ffrangio |
| Chiesi USA, INC. | $72.00 | 2023 | Kengreal |
| Abiomed | $63.65 | 2023 | Impella |
| Shockwave Medical, INC | $54.92 | 2023-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Astrazeneca Pharmaceuticals LP | $44.99 | 2024 | Lokelma, Farxiga |
| Philips North America LLC | $37.50 | 2025 | Holter, Extended Holter |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $19.88 | 2021 | |
| Inari Medical, INC. | $18.96 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $16.92 | 2020 | |
| Glaxosmithkline, LLC. | $16.67 | 2025 | Shingrix |
| Actelion Pharmaceuticals US, INC. | $15.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.